EU regulator reviews reports of rare nervous disorder after AstraZeneca vaccine

Vaccination against coronavirus disease at a doctor’s general practice, in Vienna
FILE PHOTO: Vials of the AstraZeneca's COVID-19 vaccine are seen in a general practice of a doctor, as the spread of the coronavirus disease (COVID-19) continues, in Vienna, Austria April 30, 2021. REUTERS/Leonhard Foeger

May 7, 2021

(Reuters) – Europe’s medicines regulator said on Friday it was reviewing reports of a rare condition affecting the nerves following vaccination with AstraZeneca’s COVID-19 shot, and requested the British drugmaker for more detailed data.

As part of a regular review of safety reports for the vaccine, Vaxzevria, the European Medicines Agency’s safety committee is analysing data provided on cases of Guillain-Barre syndrome, the regulator said.

AstraZeneca did not immediately respond to requests for comment.

(Reporting by Pushkala Aripaka in Bengaluru and Ludwig Burger in Frankfurt; Editing by Shinjini Ganguli)